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In the previous issue of Arthritis Research and Th  erapy, 
Ibanez and colleagues [1] report on the ‘rational’ use of 
gluco  corticoids (GCs) in the management of early arthritis. 
Th   is article concludes that GCs cause minimal varia  tion in 
bone mineral density (BMD) at multiple skeletal sites, and 
in fact may increase BMD at the ultra  distal forearm, a 
juxta-articular site. Although this article is notable for 
examining the eﬀ  ect of GCs on BMD at ﬁ  ve anatomic 
sites, a ‘rational’ use of GCs for rheumatoid arthritis (RA) 
is still elusive. To grasp the complex relation  ship between 
GCs and both localized (juxta-articular, bony erosions) 
and systemic (osteoporosis) bone loss in RA, we need to 
ﬁ  rst step back and appreciate the interplay of the immune 
system and bone metabolism.
Th   e osteoclast plays a central role at the site of inﬂ  amed 
joints and is critical in the pathogenesis of joint erosions 
in RA [2]. Receptor activator of nuclear factor-kappa B 
ligand (RANKL), expressed by TH1 and TH17 T cell 
subsets, is a potent inducer of osteoclast diﬀ  erentiation. 
Additionally, an array of pro-inﬂ  ammatory  cytokines 
such as TNF, IL-1, IL-6 and IL-17 can stimulate RANKL 
expression [3] (Figure 1). GCs, in turn, directly aﬀ  ect 
both osteoblast and osteoclast activity, and indirectly 
exert many eﬀ  ects on bone metabolism, leading to an 
increased fracture risk [4] (Figure 2).
How should the relationship between the bone biology 
in RA and the eﬀ  ects of GCs translate into the use of GCs 
in clinical practice? Th   e COBRA trial provides a rationale 
for the use of GCs in combination with other disease 
modifying anti-rheumatic drugs (DMARDs) to signiﬁ  -
cantly reduce RA disease activity [5]. A subsequent 
review demonstrates that GCs (mean cumulative dose of 
2,300 mg prednisone equivalent over the ﬁ  rst year), when 
used in combination with traditional DMARD therapy, 
can decrease the rate of radiographic progression in RA 
[6]. Th  e eﬀ  ect of GCs on bone mass, among non-RA 
patients, has been evaluated in a small randomized, 
placebo-controlled trial demonstrating that serum 
markers of bone formation are rapidly decreased among 
healthy post-menopausal women treated with just 5 mg 
of prednisone daily for 6 weeks [7]. In early RA patients 
treated with prednisolone 7.5 mg per day and traditional 
DMARD therapy (compared to traditional DMARD 
therapy alone), markers of bone formation, markers of 
bone resorption, and lumber spine BMD, but not femoral 
BMD, were decreased [8]. However, in a randomized, 
placebo-controlled trial of 95 early RA patients, GCs 
decreased the degree of localized hand bone loss [9]. 
Th  ese studies suggest that low dose GCs may reduce 
markers of bone formation leading to generalized osteo-
porosis, but they also counteract RA-associated inﬂ  am-
ma  tion and slow the rate of bone loss proximal to sites of 
active disease. Other factors, such as GC resistance and 
genetic polymorphisms that predispose to either GC 
sensitivity or resistance, may play a role in the BMD 
variation seen at various anatomic sites [10,11].
Despite the disease-modifying properties of GCs seen 
in RA patients, the risk of GC-induced osteoporosis and 
its associated morbidity often give the rheumatologist 
pause when determining whether to use GCs, in what 
dosing, for how long, at what time in the disease process, 
and in which types of RA patients (seropositive versus 
sero  negative). Ibanez and colleagues have begun to 
advance our knowledge of GC use in RA. In this cohort 
of early RA patients, they found a signiﬁ  cant decrease in 
BMD at all sites except the ultradistal and distal forearm. 
In the multivariate analysis there was no signiﬁ  cant 
relation  ship between cumulative GC use and BMD 
variation at multiple sites, except at the ultradistal 
(increased BMD) and mid-forearm (decreased BMD) [1].
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© 2010 BioMed Central LtdFigure 1. Osteoclast formation in the joint. Monocytic cells in the synovium serve as osteoclast precursors. Upon exposure to macrophage 
colony-stimulating factor (MCSF) and Receptor activator of nuclear factor-kappa B ligand (RANKL) synthesized by T cells and synovial fi  broblasts, 
osteoclasts fuse to polykaryons termed preosteoclasts, which then undergo further diff  erentiation into mature osteoclasts, acquiring specifi  c 
features such as the ruffl   ed membrane. Infl  ammatory cytokines such as TNF and IL-1, IL-6, and IL-17 increase the expression of RANKL and thus 
support osteoclastogenesis in the joint. In contrast, regulatory T cells (Tregs) block osteoclast formation via Cytotoxic T-lymphocyte antigen 4 
(CTLA4). Figure obtained with permission from [3].
Figure 2. The direct and indirect eff  ects of glucocorticoids on bone leading to glucocorticoid-induced osteoporosis and fractures. Figure 
obtained with permission from [4]. CSF, colony stimulating factor; GH, growth hormone; IGF, insulin-like growth factor; RANKL, Receptor activator of 
nuclear factor-kappa B ligand.
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variation among a cohort of early RA patients treated 
with GCs is a compelling argument for GC use - but in 
this small 2-year study of early RA, the dosing, duration 
and long-term eﬀ   ects remain unknown. Th  e apparent 
increase in ultradistal forearm BMD among patients 
treated with GCs warrants further exploration. However, 
this study of early RA examines only 116 patients treated 
with a median cumulative GC dose of 22 mg/month and 
45 mg/month among those who actually received GCs. Is 
it the relatively small cumulative dose of GCs used in this 
study that explains the lack of signiﬁ  cant BMD variation 
or the fact that only 67% of the cohort actually received 
GCs, with 17.3% of patients on GC therapy at the end of 
the study?
Conclusion
While Ibanez and colleagues have furthered our 
understanding of the eﬀ  ects of GCs on BMD variation 
through their detailed analysis of ﬁ  ve skeletal sites, we are 
far from a ‘rational’ use of GCs in the management of RA.
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